Wednesday, June 25, 2025

Qritive & Roche Redefine Cancer Diagnostics with AI

Related stories

Digital Science launches AI writing tools for Overleaf users

Digital Science announced the launch of AI Assist, an...

Centific and Virtue AI team up on responsible AI by Design

This integration delivers 30x faster multimodal protection enabling full-stack...

Vultr Gets $329M to Expand Global AI and Cloud Platform

Vultr secures $329M in credit financing to boost global...

Okta Adds Cross App Access to Secure enterprise AI Agents

Okta launches Cross App Access, a new OAuth-based protocol...

SWARM Biotactics Raises €13M to Advance Bio-Robotics

SWARM Biotactics, developer of bio-robotic systems based on fully...
spot_imgspot_img

Qritive, a leading digital pathology and AI company headquartered in Singapore, is proud to announce its collaboration with Roche, one of the largest diagnostics and life sciences companies in the world. This collaboration represents a significant milestone to advance cancer diagnostics and treatment and accelerate adoption of AI by pathologists.

With Qritive’s AI-powered solutions fully integrated with Roche navify® Digital Pathology platform, pathologists can leverage AI technology to diagnose cancer more accurately and efficiently, leading to reduced time to treatment and enhanced patient outcomes. These clinically validated AI modules, designed for colon, prostate, breast, and gastric cancers, analyze whole slide images to identify and grade tumor with precision. These tools have been shown to improve pathology reporting time by up to 10-fold and reduce the risk of misdiagnosis dramatically.

Also Read: Gilead & Genesis Partner to Develop Novel Therapies

As Bruno Occhipinti, CEO of Qritive, puts it, “we are truly excited to see how the integration of our AI-powered solutions within the highly performing Roche navify® Digital Pathology platform will augment pathologists’ performance, enabling affordable and accurate diagnostics at scale.”

Qritive‘s collaboration with Roche reinforces its commitment to empowering pathologists globally with state-of-the-art AI-powered solutions and alleviating the pressure on the healthcare system. By bringing its innovative AI-based pathology solutions to a broader audience, Qritive continues to play a pivotal role in the future of cancer diagnostics.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img